The Week in Cancer News: Targeting RAS and Thymus Health
Findings signal targeted therapy effectiveness in pancreatic cancer, and new insights into the thymus’s role in cancer and health.
Progress Against Cancer
Findings signal targeted therapy effectiveness in pancreatic cancer, and new insights into the thymus’s role in cancer and health.
At the AACR Annual Meeting 2026, National Cancer Institute Director Anthony Letai offered insights into what NCI considers to be priorities.
Heart, kidney and metabolic conditions may be linked to higher cancer risk, and a pooled cord blood therapy was found safe and similarly effective as traditional transplant in blood cancers.
In April 2026, AACR's journals editors highlighted studies on cancer survivors taking GLP-1 agonists, an immunotherapy-boosting bacteria, and more.
Injecting immunotherapy directly into precancerous oral lesions may be an effective way to prevent progression to cancer without surgery.
People with alveolar soft part sarcoma can receive immunotherapy treatment for an extended period without long-term side effects.
Rates of treatment-related leukemia rise as more people survive cancer, and cancer rates are higher in people who have never been married.
Here’s what these AACR Runners for Research had to say as they prepare to pound some pavement and raise money at the AACR Annual Meeting 2026.
Nicotine-based e-cigarettes likely increase risk for oral and lung cancers, and adjusting radiation after chemotherapy preserves low breast cancer recurrence rates.
The spring 2026 issue of Cancer Today included articles about using AI chatbots, cancer survivor—and “Survivor” winner—Ethan Zohn, and more.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More